Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SEER | US
-0.02
-1.04%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.91
1.91
1.95
1.90
Seer Inc. a life sciences company engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite an integrated solution that comprises consumables an automation instrumentation and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research and clinical trials. The company intends to sell its products for research purposes which cover academic institutions life sciences and research laboratories as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer Inc. has a collaboration agreement with Oregon Health & Science University; The Broad Institute of MIT and Harvard; Discovery Life Sciences LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences Inc. and changed its name to Seer Inc. in July 2018. Seer Inc. was incorporated in 2017 and is headquartered in Redwood City California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
30.7%1 month
49.4%3 months
43.6%6 months
52.1%-
-
0.33
0.07
0.07
1.72
0.11
-
-94.34M
117.33M
117.33M
-
-882.03
-
-23.40
-21.06
2.17
1.33
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.14
Range1M
0.34
Range3M
0.56
Rel. volume
1.06
Price X volume
591.94K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CRDF | CRDF | Biotechnology | 2.77 | 128.94M | -4.48% | n/a | 3.52% |
| Coya Therapeutics Inc. Common Stock | COYA | Biotechnology | 8.27 | 125.88M | 3.38% | n/a | 0.00% |
| ELEDON PHARMACEUTICALS INC | ELDN | Biotechnology | 3.03 | 125.39M | 2.02% | 6.60 | -7.70% |
| Werewolf Therapeutics Inc. Common Stock | HOWL | Biotechnology | 2.85 | 124.55M | 39.02% | n/a | 35.26% |
| IVVD | IVVD | Biotechnology | 1.02 | 121.83M | 5.51% | n/a | 0.48% |
| Adagene Inc. | ADAG | Biotechnology | 2.7 | 119.53M | 3.45% | n/a | 36.29% |
| PDS Biotechnology Corporation | PDSB | Biotechnology | 3.12 | 114.88M | -4.00% | n/a | 78.85% |
| Leap Therapeutics Inc | LPTX | Biotechnology | 2.98 | 114.03M | 11.40% | n/a | 0.73% |
| QSI | QSI | Biotechnology | 0.8009 | 114.02M | -1.84% | n/a | 0.71% |
| AVTX | AVTX | Biotechnology | 11.49 | 111.45M | 2.77% | n/a | -80.47% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.87 | 94.40M | 1.83% | 5.16 | 19.82% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 14.22 | 89.04M | -1.80% | 14.48 | 7.10% |
| Urban One Inc | UONEK | Broadcasting - Radio | 1.01 | 53.54M | -3.35% | n/a | 268.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.72 | - | Expensive |
| Ent. to Revenue | 0.11 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.33 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 43.62 | - | Lower Risk |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.07 | 0.25 | Cheaper |
| Market Cap | 117.33M | - | Emerging |